person · Reporting owner

Begor Mark W

Disclosed activity across 6 companies

Tapewire entity: 13729
SEC CIK: 0001335111

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
EQUIFAX INCEFX · Entity 3235	Director · CEO	July 24, 2026	July 28, 2026
FAIR ISAAC CORPFICO · Entity 3206	Director	March 21, 2018	March 22, 2018
GENERAL ELECTRIC COGE · Entity 2813	Senior Vice President	February 22, 2006	February 24, 2006
NCR Voyix CorpNCR · Entity 293	Director	September 29, 2023	October 03, 2023
RAYMOND JAMES FINANCIAL INCRJF · Entity 3126	Director	February 19, 2026	February 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

EQUIFAX INC

Report date July 24, 2026 · Filed July 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	271,890	Last balance in matching sequence After 2026-07-24 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 9 source rows Row 1 · 2026-07-24 · Exercise / conversion · Acquired 37,791 · Balance 309,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 2 · 2026-07-24 · Sale · Disposed 500 · Balance 309,181 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 3 · 2026-07-24 · Sale · Disposed 600 · Balance 308,581 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 4 · 2026-07-24 · Sale · Disposed 600 · Balance 307,981 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 5 · 2026-07-24 · Sale · Disposed 1,300 · Balance 306,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 6 · 2026-07-24 · Sale · Disposed 2,936 · Balance 303,745 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 7 · 2026-07-24 · Sale · Disposed 4,112 · Balance 299,633 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 8 · 2026-07-24 · Sale · Disposed 6,200 · Balance 293,433 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 9 · 2026-07-24 · Sale · Disposed 21,543 · Balance 271,890 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.
Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $112.46 · Expires 2028-05-04	Direct	37,792	Reported balance After 2026-07-24 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-07-24 · Exercise / conversion · Disposed 37,791 · Balance 37,792 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F11: The option vested in three equal annual increments beginning 5/4/2019.
Common StockSEC Table I · non-derivative	Indirect2-yr Apr 2025 GRAT	2,350	Reported balance Holding disclosure · report date 2026-07-24 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 2,350
Common StockSEC Table I · non-derivative	Indirect2-yr Dec 2025 GRAT	21,284	Reported balance Holding disclosure · report date 2026-07-24 · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · Balance 21,284
Common StockSEC Table I · non-derivative	Indirect2-yr Jun 2025 GRAT	38,332	Reported balance Holding disclosure · report date 2026-07-24 · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · Balance 38,332
Common StockSEC Table I · non-derivative	Indirect2-yr May 2025 GRAT	2,018	Reported balance Holding disclosure · report date 2026-07-24 · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · Balance 2,018
Common StockSEC Table I · non-derivative	Indirect2-yr May 2026 GRAT	18,562	Reported balance Holding disclosure · report date 2026-07-24 · row 14 Holding and transaction disclosures are not merged. 1 source row Row 14 · Balance 18,562

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.

F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

F11: The option vested in three equal annual increments beginning 5/4/2019.

FAIR ISAAC CORP

Report date March 21, 2018 · Filed March 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,174	Reported balance After 2018-03-21 transaction · row 1 1 source row Row 1 · 2018-03-21 · Exercise / conversion · Acquired 1,587 · Balance 3,174
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-03-21	Direct	1,586	Reported balance After 2018-03-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-21 · Exercise / conversion · Disposed 1,587 · Balance 1,586 F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board. F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board.

F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter.

GENERAL ELECTRIC CO

Report date February 22, 2006 · Filed February 24, 2006

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	7,283	Reported balance After 2006-02-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2006-02-22 · Grant · Acquired 1,057 · Balance 7,283 F1: 1-for-1 F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends.

Filing footnotes · ownership attribution and instrument terms

F1: 1-for-1

F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends.

NCR Voyix Corp

Report date September 29, 2023 · Filed October 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	951	Reported balance After 2023-09-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-29 · Grant · Acquired 951 · Balance 951 F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2: The phantom stock units are converted into common stock on a one-for-one basis. F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program.

F2: The phantom stock units are converted into common stock on a one-for-one basis.

F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director.

RAYMOND JAMES FINANCIAL INC

Report date February 19, 2026 · Filed February 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,285	Reported balance After 2026-02-19 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-02-19 · Grant · Acquired 1,303 · Balance 2,285 F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors. F2: Includes DRSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors.

F2: Includes DRSUs.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NCR Atleos Corp

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,475	Reported balance After 2025-05-21 transaction · row 1 1 source row Row 1 · 2025-05-21 · Exercise / conversion · Acquired 2,690 · Balance 31,475 F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program.

Filing footnotes · ownership attribution and instrument terms

F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionStock Option/Right to Buy · Derivative	37,791	$0.00 Strike: $112.46	$0.00	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · derivative · entry 15 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,792 Underlying: Common Stock · 37,791 shares Expires 2028-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F11 · derivative.exercise_date: The option vested in three equal annual increments beginning 5/4/2019. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	21,543	$172.00	$3,705,365.84	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 9 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,890 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F10 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	6,200	$171.26	$1,061,823.78	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 8 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,433 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F9 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	4,112	$172.79	$710,512.48	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,633 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F8 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	2,936	$173.79	$510,240.69	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,745 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	1,300	$174.91	$227,385.99	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,681 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	600	$168.47	$101,084.82	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,981 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	600	$169.86	$101,914.98	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,581 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	500	$175.85	$87,926.00	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,181 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:13 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionCommon Stock	37,791	$112.46	$4,249,975.86	Disclosure SEC source: 0001225208-26-006748 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionStock Option/Right to Buy · Derivative	37,791	$112.46 Strike: $112.46	$4,249,975.86	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · derivative · entry 10 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,583 Underlying: Common Stock · 37,791 shares Expires 2028-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vested in three equal annual increments beginning 5/4/2019. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	20,471	$172.46	$3,530,459.37	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,730 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.986 to $172.975, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	10,944	$171.57	$1,877,630.34	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,201 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.982 to $171.979, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	4,659	$173.39	$807,807.24	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,145 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.986 to $173.975, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	1,717	$174.32	$299,313.11	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,804 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.98 to $174.78, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:08 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionCommon Stock	37,791	$112.46	$4,249,975.86	Disclosure SEC source: 0001225208-26-004682 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 280 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 25, 2026 Filed Feb 27, 2026 21:14 UTC	EQUIFAX INC EFX · Entity 3235	GrantCommon Stock	40,955	$0.00	$0.00	Disclosure SEC source: 0001225208-26-002754 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,461 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 25, 2029. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 19, 2026 Filed Feb 23, 2026 20:28 UTC	RAYMOND JAMES FINANCIAL INC RJF · Entity 3126	GrantCommon Stock	1,303	$0.00	$0.00	Disclosure SEC source: 0001225208-26-002376 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,285 F1 · shares: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors. F2 · balance_after: Includes DRSUs. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionStock Option/Right to Buy · Derivative	37,791	$0.00 Strike: $112.46	$0.00	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · derivative · entry 20 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,374 Underlying: Common Stock · 37,791 shares Expires 2028-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option vested in three equal annual increments beginning 5/4/2019. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	18,352	$202.15	$3,709,939.38	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 14 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,506 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F13 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $201.67 to $202.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	11,000	$203.08	$2,233,871.20	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 13 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,858 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F12 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $202.665 to $203.64, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	4,057	$201.26	$816,522.37	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 12 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,858 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F11 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $200.672 to $201.66, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	1,772	$200.03	$354,451.92	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 11 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,915 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F10 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $199.67 to $200.481, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	Tax withholdingCommon Stock	1,759	$202.71	$356,566.89	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 10 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,687 F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	829	$199.00	$164,971.83	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 9 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,446 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F9 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $198.645 to $199.62, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	445	$196.43	$87,410.46	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 8 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F8 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $196.123 to $196.912, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	364	$195.40	$71,124.84	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,720 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $194.892 to $195.779, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	331	$194.22	$64,287.15	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $193.735 to $194.661, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	227	$192.89	$43,785.01	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,415 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $192.556 to $193.366, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	213	$203.76	$43,401.03	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,642 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $203.675 to $203.85, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	201	$197.79	$39,755.57	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,855 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $197.524 to $198.008, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	GrantCommon Stock	33,278	$0.00	$0.00	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,056 F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:08 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionCommon Stock	37,791	$112.46	$4,249,975.86	Disclosure SEC source: 0001225208-26-001770 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 03, 2026 Filed Feb 5, 2026 20:14 UTC	EQUIFAX INC EFX · Entity 3235	Tax withholdingCommon Stock	2,405	$175.05	$420,995.25	Disclosure SEC source: 0001225208-26-001347 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,987 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
February 03, 2026 Filed Feb 5, 2026 20:14 UTC	EQUIFAX INC EFX · Entity 3235	GrantCommon Stock	59,123	$0.00	$0.00	Disclosure SEC source: 0001225208-26-001347 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,392 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
December 31, 2025 Filed Jan 5, 2026 21:11 UTC	EQUIFAX INC EFX · Entity 3235	Tax withholdingCommon Stock	997	$216.98	$216,329.06	Disclosure SEC source: 0001225208-26-000154 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,091 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	Exercise / conversionStock Option/Right to Buy · Derivative	27,959	$0.00 Strike: $191.44	$0.00	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · derivative · entry 22 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,959 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/21/2021. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	5,872	$230.16	$1,351,500.11	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 16 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 22,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F15 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $229.7507 to $230.7266, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	5,274	$232.27	$1,224,994.09	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 15 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 27,917 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F14 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $231.845 to $232.81, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	3,995	$229.12	$915,337.20	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 14 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 33,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F13 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $228.73 to $229.685, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	3,331	$231.59	$771,439.28	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 13 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 37,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F12 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $230.83 to $231.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	2,801	$233.12	$652,979.48	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 12 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 40,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F11 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $232.85 to $233.80, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	76	$234.93	$17,854.68	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 11 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 43,318 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	37	$233.95	$8,656.03	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 10 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · 2-yr Jun 2025 GRAT Disclosed balance after: 43,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F10 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $233.88 to $234.215, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	6,943	$232.19	$1,612,086.14	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 9 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,934 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F9 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $231.735 to $232.71, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	6,639	$230.18	$1,528,191.58	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 8 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F8 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $229.74 to $230.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	6,227	$229.20	$1,427,254.55	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,516 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $228.73 to $229.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	4,015	$233.01	$935,548.80	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,743 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $232.74 to $233.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	3,757	$231.46	$869,589.58	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,758 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $230.74 to $231.734, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document
October 27, 2025 Filed Oct 29, 2025 20:09 UTC	EQUIFAX INC EFX · Entity 3235	SaleCommon Stock	204	$235.22	$47,985.08	Disclosure SEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,515 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $234.93 to $235.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.